1. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
    Pauline Rottier et al, 2023, Frontiers in Oncology CrossRef
  2. Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
    Wei Wang et al, 2023, Technology in Cancer Research & Treatment CrossRef
  3. The prognostic value of absolute lymphocyte count and neutrophil‐to‐lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta‐analysis
    Bulin Sang et al, 2024, Frontiers in Oncology CrossRef
  4. Effect of Radiation Therapy on Composition of Lymphocyte Populations in Patients with Primary Breast Cancer
    Irina Kobzeva et al, 2023, Journal of Personalized Medicine CrossRef
  5. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
    Alberto D’Angelo et al, 2022, Current Issues in Molecular Biology CrossRef
  6. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang et al, 2024, BMC Cancer CrossRef
  7. Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part II. Hematological Markers of Inflammation
    Natalia S. Sergeeva et al, 2023, Annals of the Russian academy of medical sciences CrossRef